Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19075
Title: ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
Authors: Scheffer, Ingrid E;Berkovic, Samuel F;Capovilla, Giuseppe;Connolly, Mary B;French, Jacqueline;Guilhoto, Laura;Hirsch, Edouard;Jain, Satish;Mathern, Gary W;Moshé, Solomon L;Nordli, Douglas R;Perucca, Emilio;Tomson, Torbjörn;Wiebe, Samuel;Zhang, Yue-Hua;Zuberi, Sameer M
Affiliation: School of Medicine, University of Glasgow, Glasgow, United Kingdom
Department of Pediatrics, Peking University First Hospital, Beijing, China
Paediatric Neurosciences Research Group, Fraser of Allander Neurosciences Unit, Royal Hospital for Children, Glasgow, United Kingdom
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Paediatrics, Royal Children's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
Florey Institute, Melbourne, Victoria, Australia
Child Neuropsychiatry Department, Epilepsy Center, C. Poma Hospital, Mantova, Italy
Department of Pediatrics, British Columbia's Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Department of Neurology, NYU School of Medicine, New York, New York, U.S.A
Department of Neurology, Federal University of São Paulo; University Hospital, University of São Paulo, São Paulo, Brazil
University Hospital INSERM U 964, Strasbourg, France
IDÉE, Lyon, France
Indian Epilepsy Centre, New Delhi, India
Departments of Neurosurgery, Psychiatry and Biobehavioral Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, U.S.A
Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience and Department of Pediatrics, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, U.S.A
Division of Neurology, Children's Hospital Los Angeles, Los Angeles, California, U.S.A
C. Mondino National Neurological Institute and Clinical Pharmacology Unit, University of Pavia, Pavia, Italy
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
Issue Date: Apr-2017
EDate: 2017-03-08
Citation: Epilepsia 2017; 58(4): 512-521
Abstract: The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19075
DOI: 10.1111/epi.13709
ORCID: 0000-0002-2311-2174
0000-0003-4580-841X
PubMed URL: 28276062
Type: Journal Article
Subjects: Classification
Epilepsy syndromes
Etiology
Terminology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.